BEAM
Beam Therapeutics Inc
$
24.250
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
25.190
Open
24.670
VWAP
23.96
Vol
2.90M
Mkt Cap
2.45B
Low
23.040
Amount
69.52M
EV/EBITDA(TTM)
--
Total Shares
82.31M
EV
1.38B
EV/OCF(TTM)
--
P/S(TTM)
36.85
Beam Therapeutics Inc. is a biotechnology company developing precision genetic medicines through base editing. The Company's suite of gene editing technologies is anchored by base editing, a technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the deoxyribonucleic acid. Its lead programs are focused on sickle cell disease and alpha-1 antitrypsin deficiency, and it is also advancing programs in other genetic diseases. Its primary programs include BEAM-101, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-302 and BEAM-301. BEAM-101 is a patient-specific, autologous hematopoietic stem cell (HSC), investigational therapy. ESCAPE is a potentially non-genotoxic approach to HSC transplantation. BEAM-302 is a liver-targeting lipid nanoparticle formulation of base editing reagents designed to offer a one-time treatment to correct the E342K point mutation (PiZZ genotype).
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q3
FY2025Q4
FY2026Q1
12.72M
-10.82%
-1.027
-12.21%
13.54M
-54.96%
-1.061
-2.65%
16.83M
+125.35%
-1.012
-18.39%
Estimates Revision
The market is revising Downward the revenue expectations for Beam Therapeutics Inc. (BEAM) for FY2025, with the revenue forecasts being adjusted by -19.51% over the past three months. During the same period, the stock price has changed by 26.83%.
Revenue Estimates for FY2025
Revise Downward
-19.51%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
-4.32%
In Past 3 Month
Stock Price
Go Up
+26.83%
In Past 3 Month
13 Analyst Rating
74.02% Upside
Wall Street analysts forecast BEAM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BEAM is 42.20 USD with a low forecast of 20.00 USD and a high forecast of 80.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
11 Buy
2 Hold
0 Sell
Strong Buy
74.02% Upside
Current: 24.250
Low
20.00
Averages
42.20
High
80.00
74.02% Upside
Current: 24.250
Low
20.00
Averages
42.20
High
80.00
Wedbush
David Nierengarten
Neutral
downgrade
$14 -> $9
2025-10-30
New
Reason
Wedbush
David Nierengarten
Price Target
$14 -> $9
2025-10-30
New
downgrade
Neutral
Reason
Wedbush analyst David Nierengarten lowered the firm's price target on Intellia Therapeutics (NTLA) to $9 from $14 and keeps a Neutral rating on the shares. The firm notes FDA placed a clinical hold on the Phase 3 MAGNITUDE and MAGNITUDE-2 trials of nex-z following a voluntary pause due to new safety signals of symptomatic transaminase elevation and bilirubin increase. A formal Clinical Hold Letter will be provided within 30 days. Wedbush reiterates its position that these safety signals appear target-specific rather than a class effect of LNP delivery, and views recent price action for Beam Therapeutics (BEAM) and Prime Medicine (PRME) as a buying opportunity. For Intellia's nex-z, even after the clinical hold is resolved, the firm expects reduced market uptake against competing siRNA therapies, which do not have substantial reports of hepatic toxicity and can be discontinued in the case of adverse events.
HC Wainwright & Co.
Patrick Trucchio
Strong Buy
Reiterates
$80
2025-04-07
Reason
HC Wainwright & Co.
Patrick Trucchio
Price Target
$80
2025-04-07
Reiterates
Strong Buy
Reason
B of A Securities
Alec Stranahan
Hold
to
Strong Buy
Upgrades
$42
2025-03-28
Reason
B of A Securities
Alec Stranahan
Price Target
$42
2025-03-28
Upgrades
Hold
to
Strong Buy
Reason
Cantor Fitzgerald
Rick Bienkowski
Buy
Reiterates
n/a
2025-03-12
Reason
Cantor Fitzgerald
Rick Bienkowski
Price Target
n/a
2025-03-12
Reiterates
Buy
Reason
HC Wainwright & Co.
Patrick Trucchio
Strong Buy
Reiterates
$80
2025-03-10
Reason
HC Wainwright & Co.
Patrick Trucchio
Price Target
$80
2025-03-10
Reiterates
Strong Buy
Reason
Jones Trading
Soumit Roy
Hold
to
Strong Buy
Upgrades
$34
2025-03-10
Reason
Jones Trading
Soumit Roy
Price Target
$34
2025-03-10
Upgrades
Hold
to
Strong Buy
Reason
JonesResearch upgraded Beam Therapeutics to Buy from Hold with a $34 price target.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Beam Therapeutics Inc (BEAM.O) is -5.88, compared to its 5-year average forward P/E of -11.01. For a more detailed relative valuation and DCF analysis to assess Beam Therapeutics Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-11.01
Current PE
-5.88
Overvalued PE
-3.04
Undervalued PE
-18.99
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-9.18
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.27
Undervalued EV/EBITDA
-18.63
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
171.13
Current PS
24.25
Overvalued PS
511.18
Undervalued PS
-168.92
Financials
Annual
Quarterly
FY2025Q2
YoY :
-28.08%
8.47M
Total Revenue
FY2025Q2
YoY :
+14.54%
-120.15M
Operating Profit
FY2025Q2
YoY :
+12.34%
-102.29M
Net Income after Tax
FY2025Q2
YoY :
-9.91%
-1.00
EPS - Diluted
FY2025Q2
YoY :
-6.34%
-79.59M
Free Cash Flow
FY2025Q2
YoY :
0.00%
100.00
Gross Profit Margin - %
FY2025Q2
YoY :
+1255.90%
-589.95
FCF Margin - %
FY2025Q2
YoY :
+56.22%
-1.21K
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
32.9K
USD
3
3-6
Months
1.0M
USD
3
6-9
Months
1.4M
USD
6
0-12
Months
860.7K
USD
3
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 161.22% over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
377.0K
Volume
2
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
8
2.4M
Volume
Months
0-12
2
929.1K
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
32.9K
USD
3
3-6
Months
1.0M
USD
3
6-9
Months
1.4M
USD
6
0-12
Months
860.7K
USD
3
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
BEAM News & Events
Events Timeline
2025-10-27 (ET)
2025-10-27
13:53:13
Video: This Stock is Weighing Down the In Vivo Gene Editing Therapy Sector
2025-09-03 (ET)
2025-09-03
12:45:37
Clear Street: Beam Maintains Strong Competitive Position Following Wave Data
2025-08-14 (ET)
2025-08-14
07:20:58
Beam Therapeutics announces U.S. FDA granted RMAT to BEAM-101
Sign Up For More Events
Sign Up For More Events
News
6.5
10-07CNBCCramer's Lightning Round: Affirm is a Recommended Purchase
3.0
09-29NASDAQ.COMExplore the Details: VB Shows Potential for 14% Growth
6.5
09-18BenzingaMy Leading Biotech Stock Selections and Investment Approach for the Coming 3-10 Years
Sign Up For More News
People Also Watch
GOOG
Alphabet Inc
284.120
USD
+0.82%
META
Meta Platforms Inc
637.710
USD
-1.64%
AVGO
Broadcom Inc
362.550
USD
-1.92%
WMT
Walmart Inc
101.590
USD
+0.41%
AMZN
Amazon.com Inc
254.000
USD
+4.00%
TSLA
Tesla Inc
468.370
USD
+2.59%
MSFT
Microsoft Corp
517.030
USD
-0.15%
NVDA
NVIDIA Corp
206.880
USD
+2.17%
AAPL
Apple Inc
269.050
USD
-0.49%
GOOGL
Alphabet Inc
283.720
USD
+0.90%
FAQ
What is Beam Therapeutics Inc (BEAM) stock price today?
The current price of BEAM is 24.25 USD — it has decreased -3.04 % in the last trading day.
What is Beam Therapeutics Inc (BEAM)'s business?
What is the price predicton of BEAM Stock?
What is Beam Therapeutics Inc (BEAM)'s revenue for the last quarter?
What is Beam Therapeutics Inc (BEAM)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Beam Therapeutics Inc (BEAM)'s fundamentals?
How many employees does Beam Therapeutics Inc (BEAM). have?